Cargando…

Incidental regression of an advanced basal cell carcinoma after ipilimumab exposure for metastatic melanoma

Detalles Bibliográficos
Autores principales:	Mohan, Shalini V., Kuo, Karen Y., Chang, Anne Lynn S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2016
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4809440/ https://www.ncbi.nlm.nih.gov/pubmed/27051815 http://dx.doi.org/10.1016/j.jdcr.2015.11.007

Ejemplares similares

Advanced Basal Cell Carcinoma: Epidemiology and Therapeutic Innovations
por: Mohan, Shalini V., et al.
Publicado: (2014)

Complete regression of mycosis fungoides after ipilimumab therapy for advanced melanoma
por: Bar-Sela, Gil, et al.
Publicado: (2015)

Bullous pemphigoid associated with ipilimumab therapy for advanced metastatic melanoma
por: Hanley, T, et al.
Publicado: (2018)

Ipilimumab Pharmacotherapy in Patients with Metastatic Melanoma
por: Jeter, Joanne M., et al.
Publicado: (2012)

Ipilimumab cystic hypophysitis mimicking metastatic melanoma
por: Wallace, John, et al.
Publicado: (2018)

Prognostic biomarkers for immunotherapy with ipilimumab in metastatic melanoma
por: Nyakas, M., et al.
Publicado: (2019)

Acute visual loss after ipilimumab treatment for metastatic melanoma
por: Wilson, Melissa A., et al.
Publicado: (2016)

Patterns of response with talimogene laherparepvec in combination with ipilimumab or ipilimumab alone in metastatic unresectable melanoma
por: Chesney, Jason, et al.
Publicado: (2019)

Ipilimumab-Induced Neutropenia in Melanoma
por: Ban-Hoefen, Makiko, et al.
Publicado: (2016)

Profile of ipilimumab and its role in the treatment of metastatic melanoma
por: Patel, Sapna P, et al.
Publicado: (2011)

Ipilimumab in the treatment of metastatic melanoma: management of adverse events
por: Della Vittoria Scarpati, Giuseppina, et al.
Publicado: (2014)

Predictors of toxicity for metastatic melanoma patients treated with ipilimumab
por: Valpione, Sara, et al.
Publicado: (2015)

Retrospective Analysis of Rechallenge with Ipilimumab in Patients with Metastatic Melanoma
por: Formozo, A. A., et al.
Publicado: (2021)

The Predicted Impact of Ipilimumab Usage on Survival in Previously Treated Advanced or Metastatic Melanoma in the UK
por: Larkin, James, et al.
Publicado: (2015)

Ipilimumab for advanced melanoma: A pharmacologic perspective
por: Trinh, Van Anh, et al.
Publicado: (2013)

Nivolumab plus ipilimumab in the treatment of advanced melanoma
por: Tsai, Katy K., et al.
Publicado: (2015)

Large granular lymphocytosis with severe neutropenia following ipilimumab therapy for metastatic melanoma
por: Wei, Guoqing, et al.
Publicado: (2012)

Ipilimumab: A First-in-Class T-Cell Potentiator for Metastatic Melanoma
por: Chmielowski, Bartosz
Publicado: (2013)

Myasthenia Gravis Induced by Ipilimumab in a Patient With Metastatic Melanoma
por: Montes, Vera, et al.
Publicado: (2018)

Body composition is prognostic and predictive of ipilimumab activity in metastatic melanoma
por: Chu, Michael P., et al.
Publicado: (2020)

Real World Outcomes of Ipilimumab and Nivolumab in Patients with Metastatic Melanoma
por: Asher, Nethanel, et al.
Publicado: (2020)

Ipilimumab: Melanoma and beyond
por: Patel, Vishal, et al.
Publicado: (2011)

Ipilimumab, a Promising Immunotherapy with Increased Overall Survival in Metastatic Melanoma?
por: Piérard, Gérald E., et al.
Publicado: (2012)

Bilateral neuroretinitis and anterior uveitis following ipilimumab treatment for metastatic melanoma
por: Hahn, Laura, et al.
Publicado: (2016)

Treatment of Ipilimumab Induced Graves' Disease in a Patient with Metastatic Melanoma
por: Azmat, Umal, et al.
Publicado: (2016)

Metastatic melanoma patients’ sensitivity to ipilimumab cannot be predicted by tumor characteristics
por: Rossfeld, Kara, et al.
Publicado: (2017)

Ipilimumab and Nivolumab-Induced Colitis in a Patient With Recurrent Metastatic Melanoma
por: Moein, Hamid-Reza, et al.
Publicado: (2021)

Long-term real-world experience with ipilimumab and non-ipilimumab therapies in advanced melanoma: the IMAGE study
por: Dalle, Stéphane, et al.
Publicado: (2021)

Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma
por: Wolchok, Jedd D., et al.
Publicado: (2022)

Trough levels of ipilimumab in serum as a potential biomarker of clinical outcomes for patients with advanced melanoma after treatment with ipilimumab
por: Koguchi, Yoshinobu, et al.
Publicado: (2021)

Efficacy and safety of ipilimumab in patients with advanced melanoma and brain metastases
por: Queirolo, Paola, et al.
Publicado: (2014)

Use of ipilimumab in the treatment of melanoma
por: Acharya, Utkarsh H, et al.
Publicado: (2013)

Sequential treatment with ipilimumab and BRAF inhibitors in patients with metastatic melanoma: data from the Italian ipilimumab expanded access programme (EAP)
por: Ascierto, Paolo Antonio, et al.
Publicado: (2013)

Healthcare cost comparison analysis of nivolumab in combination with ipilimumab versus nivolumab monotherapy and ipilimumab monotherapy in advanced melanoma
por: Potluri, Ravi, et al.
Publicado: (2019)

T cell receptor diversity evaluation to predict patient response to Ipilimumab in metastatic melanoma
por: Postow, Michael, et al.
Publicado: (2014)

The impact of body composition parameters on ipilimumab toxicity and survival in patients with metastatic melanoma
por: Daly, Louise E, et al.
Publicado: (2017)

Sneaky side effects and ineffectiveness of an immunotherapy with ipilimumab in a case of metastatic melanoma
por: Krecké, Nathalie, et al.
Publicado: (2016)

Influence of ipilimumab on expanded tumour derived T cells from patients with metastatic melanoma
por: Bjoern, Jon, et al.
Publicado: (2017)

Nivolumab and Ipilimumab in the Treatment of Metastatic Uveal Melanoma: A Single-Center Experience
por: Karivedu, Vidhya, et al.
Publicado: (2019)

Onset of azoospermia in man treated with ipilimumab/nivolumab for BRAF negative metastatic melanoma
por: Rabinowitz, Matthew J., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_439c786gq3c0a6dh49bv3bb4og